Ireland
--:--IST
Recruiting Observational

Retinal Neurovascular Coupling in Patients Previously Infected With COVID-19

NCT05650905 · tracked via the Priya Life Science Austria tracker
Phase
Observational
Started
2021-07-26
Last updated
2025-05-16

Condition(s) studied

COVID-19Post-COVID-19 Syndrome

Investigational drug(s) / intervention(s)

Dynamic Vessel Analyzer (DVA)Fourier domain optical coherence tomography (FDOCT)Optical coherence tomography (OCT)Laser Speckle Flowgraphy (LSFG)Proteomics and Metabolites in Plasma, tear fluid and finger sweat

Dynamic Vessel Analyzer (DVA): Retinal neurovascular coupling, Retinal vessel diameters and Retinal oxygen saturation will be assessed using the DVA

Fourier domain optical coherence tomography (FDOCT): Retinal blood velocities and Retinal blood flow will be assessed using the FDOCT

Optical coherence tomography (OCT): Retinal nerve fiber layer thickness, Central retinal thickness and Retinal vessel density will be assessed using the OCT

Laser Speckle Flowgraphy (LSFG): Normalized blur and Relative flow volume will be assessed using the LSFG

Proteomics and Metabolites in Plasma, tear fluid and finger sweat: Proteomics and Metabolites in Plasma, tear fluid and finger sweat will be assessed using a Blooddraw, filter paper and Schirmer-test

Study summary

The Study objective is to measure retinal neurovascular coupling and blood flow parameters in patients previously infected with COVID-19, long COVID-19 and healthy age- and sex- matched control subjects

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Inclusion criteria for healthy subjects * Men and women aged over 18 years * Non-smokers * Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant * No previous history of COVID-19 infection * Negative testing for SARS-CoV-2 seroprevalence using nucleocapsid antibody tests * Negative PCR test for SARS-CoV-2 * Normal ophthalmic findings, ametropy \< 6 Dpt. Inclusion criteria for subjects with history of COVID-19 infection * Men and women aged over 18 years * Non-smokers * History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history) within the last 6 months * Positive testing for SARS-CoV-2 seroprevalence using spike protein IgG antibody tests * Negative PCR test for SARS-CoV-2 Inclusion criteria for subjects with long COVID-19 * Men and women aged over 18 years * Non-smokers * History of COVID-19 infection (confirmed by a positive PCR test for SARS-CoV2 in the medical history) * Positive testing for SARS-CoV-2 seroprevalence * Negative PCR test for SARS-CoV-2 * Long Covid according to the latest WHO-Guidelines Exclusion Criteria: Any of the following will exclude a healthy control subject from the study: * Symptoms of a clinically relevant illness in the 3 weeks before the first study day * Presence or history of a severe medical condition as judged by the clinical investigator * Participation in a clinical trial in the 3 weeks preceding the study * Blood donation during the previous three weeks * History or family history of epilepsy * Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator * Best corrected visual acuity \< 0.8 Snellen * Pregnancy, planned pregnancy or lactatin * History of epilepsia Any of the following will exclude a subject with history of COVID-19 infection from the study: * Blood donation during the previous three weeks * History or family history of epilepsy * Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator * Best corrected visual acuity \< 0.8 Snellen * Ametropy \>6 Dpt * Pregnancy, planned pregnancy or lactating * History of epilepsia Any of the following will exclude a subject with long COVID-19 from the study: * Blood donation during the previous three weeks * History or family history of epilepsy * Presence of any abnormalities preventing reliable measurements in the study eye as judged by the investigator * Best corrected visual acuity \< 0.8 Snellen * Ametropy \>6 Dpt * Pregnancy, planned pregnancy or lactating * History of epilepsia * Diabetes mellitus

Primary outcome measure(s)

  • Retinal neurovascular coupling — Day 0
    Retinal neurovascular coupling will be assessed using the DVA

Trial sites (1)

FacilityCityRegionStatus
Medical University of Vienna, Department of Clinical Pharmacology Vienna State of Vienna Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05650905 on ClinicalTrials.gov ↗ ← All trials in Austria